AMGN Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$303.01 |
| 52 Week High | US$346.85 |
| 52 Week Low | US$253.30 |
| Beta | 0.56 |
| 1 Month Change | 10.81% |
| 3 Month Change | 2.88% |
| 1 Year Change | 4.78% |
| 3 Year Change | 33.47% |
| 5 Year Change | 51.71% |
| Change since IPO | 215,373.78% |
Recent News & Updates
Recent updates
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Feb 06Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.38
Feb 01
Amgen: Likely To Be Rangebound (Rating Downgrade)
Jan 20Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's
Jan 17Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold
Jan 05Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38
Dec 14Amgen: MariTide Underwhelms, But There Are Ways To Win
Nov 26Here's Why Amgen (NASDAQ:AMGN) Has A Meaningful Debt Burden
Nov 26Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Shareholder Returns
| AMGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 2.3% | -0.4% |
| 1Y | 4.8% | -1.4% | 20.8% |
Return vs Industry: AMGN exceeded the US Biotechs industry which returned -1.4% over the past year.
Return vs Market: AMGN underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| AMGN volatility | |
|---|---|
| AMGN Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMGN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 28,000 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| AMGN fundamental statistics | |
|---|---|
| Market cap | US$160.05b |
| Earnings (TTM) | US$4.09b |
| Revenue (TTM) | US$33.42b |
39.8x
P/E Ratio4.9x
P/S RatioIs AMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGN income statement (TTM) | |
|---|---|
| Revenue | US$33.42b |
| Cost of Revenue | US$10.46b |
| Gross Profit | US$22.97b |
| Other Expenses | US$18.88b |
| Earnings | US$4.09b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.61 |
| Gross Margin | 68.71% |
| Net Profit Margin | 12.24% |
| Debt/Equity Ratio | 1,022.6% |
How did AMGN perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield118%
Payout RatioDoes AMGN pay a reliable dividends?
See AMGN dividend history and benchmarks| Amgen dividend dates | |
|---|---|
| Ex Dividend Date | Feb 14 2025 |
| Dividend Pay Date | Mar 07 2025 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 13 days |
Does AMGN pay a reliable dividends?
See AMGN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 22:36 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amgen Inc. is covered by 62 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |